The molecular pharmacology of glucagon agonists in diabetes and obesity

Within recent decades glucagon receptor (GcgR) agonism has drawn attention as a therapeutic tool for the treatment of type 2 diabetes and obesity. In both mice and humans, glucagon administration enhances energy expenditure and suppresses food intake suggesting a promising metabolic utility. Therefo...

Descripción completa

Detalles Bibliográficos
Autores principales: Novikoff, Aaron, Müller, Timo D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Science Inc 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10265134/
https://www.ncbi.nlm.nih.gov/pubmed/36997003
http://dx.doi.org/10.1016/j.peptides.2023.171003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10265134/
https://www.ncbi.nlm.nih.gov/pubmed/36997003
http://dx.doi.org/10.1016/j.peptides.2023.171003

Ejemplares similares